Leukemia

Subscribe to Selected New Research on Leukemia

33478 relevant articles (1827 outcomes, 3828 trials/studies) found for this Disease

Description: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Also Known As:

Leukemias

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Histologic Type: 1

Leukemia: 33478

Myeloid Leukemia: 2535

Lymphoid Leukemia: 1273

Hairy Cell Leukemia: 1244

Enzootic Bovine Leukosis: 254

Plasma Cell Leukemia: 214

Experimental Leukemia: 63

Mast-Cell Leukemia: 54

Feline Leukemia: 41

Radiation-Induced Leukemia: 23

Related Diseases

1.	Neoplasms (Cancer)
2.	Lymphoma (Lymphomas)
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

Experts

1.	Grant, Steven: 36 articles (08/2008 - 01/2002)
2.	Dent, Paul: 25 articles (09/2007 - 01/2002)
3.	Larson, Richard A: 22 articles (10/2008 - 03/2002)
4.	Cancer and Leukemia Group B: 21 articles (04/2008 - 05/2003)
5.	Kantarjian, Hagop: 20 articles (08/2008 - 03/2002)
6.	Rahmani, Mohamed: 20 articles (08/2008 - 01/2002)
7.	Garcia-Manero, Guillermo: 18 articles (08/2008 - 02/2002)
8.	Cortes, Jorge: 17 articles (08/2008 - 03/2002)
9.	Chung, Jing-Gung: 16 articles (01/2008 - 11/2004)
10.	Small, Eric J: 15 articles (09/2008 - 08/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Leukemia:

1.	Cytarabine (Cytosar-U)FDA LinkGeneric 08/01/2000 - "The antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) has been used as a highly effective agent for the treatment of leukemia. " 01/01/1999 - "Since in Japan, high-dose cytarabine for acute leukemia is not covered by health insurance, post-remission therapy might be less intense compared to western countries and it takes a long time to complete the therapy. " 03/01/1996 - "A diagnosis of hypoplastic mixed lineage leukemia was made and treated with low dose cytosine arabinoside, he resulted in complete remission. " 07/01/1992 - "He was treated with BHAC-DMP and intermediate-dose ara-C therapy for leukemia and a complete remission was obtained by March 25, 1988. " 10/01/1988 - "Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine." Order ALL the reference details at left...
2.	AntigensIBA 06/01/2005 - "(2) Cord blood derived mature DC presenting leukemia antigen can generate leukemia-specific CTL with vigorous cytotoxic activity against the same leukemia blasts and low killing activity against bone marrow cells of the same patients in complete remission phase." 01/01/1987 - "Analysis of the antigen expression by individual cells within the parental and the selected cell populations was achieved by flow cytometry and demonstrated a marked decrease of the leukemia-associated antigen expression on individual cells within the selected subpopulation. " 11/01/2008 - "In conclusion, haplo-HSCT can be an alternative option for the treatment of high-risk acute leukemia patients in remission, lacking a human leukocyte antigen-matched donor." 09/01/2004 - "After HGF gene transfer, acute GVHD was reduced, while mature donor T-cell responses to host antigens were preserved, resulting in a significant improvement of leukemia-free survival. " 01/01/2005 - "Improved immune responses can be established by the differentiation of AML blasts into AML-derived dendritic cells (DC) thereby conserving their intrinsic leukemia specific antigens and obtaining full capacity to present these antigens to naive T cells. " Order ALL the reference details at left...
3.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/01/1991 - "In a third group of new regimens reporting improved antileukemia efficacy and increased leukemia-free survival, results are not convincingly superior to cyclophosphamide and total body radiation. " 12/01/1985 - "Protection also was observed in EL-4-bearing mice that were treated with cyclophosphamide (CY) rather than by immunization, however, the protective effects were observed only when CY treatment was instituted 6 days after inoculation of live leukemia cells. " 01/15/1997 - "RESULTS: The disease process in leukemic mice was retarded substantially by combination treatment with cyclophosphamide and specific bcr/abl antisense [S]ODNs (P < .001, relative to treatment with specific antisense [S]ODNs alone, cyclophosphamide alone, or cyclophosphamide plus nonspecific [i.e., control] antisense [S]ODNs); 50% of the mice treated with cyclophosphamide and specific antisense [S]ODNs appeared to be cured of leukemia. " 01/01/2000 - "Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide." 01/01/1991 - "Factors influencing remission post-BMT in patients with acute and chronic leukemia prepared with cyclophosphamide and total body irradiation (TBI)." Order ALL the reference details at left...
4.	imatinib (Gleevec)FDA Link 01/01/2004 - "Although Imatinib, the first molecularly targeted drug developed for CML has achieved a remarkable success, the emergence of resistance to this agent mitigates the prospect of a cure for this leukemia. " 11/01/2008 - "Treatment with imatinib is very effective in Bcr-Abl positive leukemia. " 01/01/2007 - "QRT-PCR, due to its superior sensitivity, is considered the gold standard for the follow-up of Ph+ leukemias treated with imatinib. " 07/01/2009 - "Imatinib mesylate is effective against Ph chromosome-positive leukemia; however, resistance has been reported. " 12/15/2003 - "CONCLUSIONS: Imatinib mesylate was found to be effective in inducing undetectable residual disease in a small cohort of pediatric patients with Ph+ leukemia. " Order ALL the reference details at left...
5.	Methotrexate (Mexate)FDA LinkGeneric 01/01/1978 - "The leukemia became manifest while the patient was in a remarkable remission brought about by treatment with high-dose methotrexate with citrovorum rescue. " 01/01/1979 - "At the present time, a successful regimen for the eradication of occult meningeal leukemia, following induction of a first complete remission in acute lymphoid and undifferentiated childhood leukemia, is the combination of cranial radiotherapy in a dose of 1800 rads in 10 fractions in 12--14 days with six doses of intrathecal methotrexate. " 09/01/1992 - "After the first relapse of the central nervous system (CNS) leukemia, intrathecal administration of methotrexate (MTX) and skull irradiation induced CNS remission. " 01/01/1983 - "Bone marrow cells from children with leukemia in remission and lymphoblasts and myeloblasts from children with early and late-stage leukemia all accumulated methotrexate during short-term culture and converted it to poly-gamma-glutamyl derivatives. " 01/01/1979 - "Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir." Order ALL the reference details at left...
6.	Interleukin-2 (IL2)IBA 12/01/1997 - "A similar phase I trial of IL-2 after alloBMT was also performed in children with acute leukemia beyond first complete remission. " 01/01/1989 - "In the current study we used the therapy of established murine leukemia to identify the lymphocyte subsets responsible for toxicity and for therapeutic efficacy of high-dose IL-2. " 05/01/1997 - "Adoptive transfer of CD3AK cells with low dose rIL-2 into the P 388 mice significantly enhanced the splenocyte proliferation (SP) induced by Con A, the NK cell activity and the splenocytic IL-2 production and prolonged their survival (45.19%); CTX (200 mg/kg) alone prolonged the survival of P 388-bearing mice (29.90%), but further decreased the immunodeficiency; combination of CTX and CD3AK passive transfer could prevent the reduction of SP, NK activity and IL-2 production in the leukemic mice and prolonged the survival (59.45%), combination of KSC and adoptively transfected CD2AK cells and/or CTX had a much better therapeutic efficacy for P 388 murine leukemia, 12.50%-75.00% of the leukemic mice were cured. " 01/01/1989 - "Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia." 09/01/1991 - "Anti-CD3 + IL-2 activated cells from patients with ALL and NHL who had received autologous BMT and cells from patients with leukemia who underwent allogeneic BMT were more effective in lysing the natural killer (NK) sensitive target, K562, and the NK-resistant target, Daudi, compared with controls. " Order ALL the reference details at left...
7.	Etoposide (VP 16)FDA LinkGeneric 01/01/1987 - "Although CR was not achieved in any patients with acute leukemia, and PR was in three (33.3%), it was found that etoposide was most effective for the patients with the M4 or M5 subtype in the FAB classification. " 07/01/1995 - "After she had been treated with low dose etoposide for leukemia, she obtained complete remission. " 07/01/1998 - "We evaluated the efficacy of a preparatory regimen consisting of fractionated total body irradiation (TBI) (12 Gy in six fractions) and high dose etoposide (60 mg/kg) administered as an 8-h infusion for allogeneic BMT in 16 consecutive patients with acute leukemia. " 01/01/1990 - "In leukemias with monocytic phenotype (M4-M5), the remission rate was significantly higher with the etoposide-containing regimen (p = 0.02). " 10/01/1992 - "We conclude that combining VP-16 and CsA was effective in purging MDR leukemia cells from transplanted BM in this murine model." Order ALL the reference details at left...
8.	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/01/2002 - "All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype." 07/15/1997 - "All-trans retinoic acid (ATRA) has been used for APL patients as a potent therapeutic agent to induce differentiation of leukemia cells. " 10/01/1995 - "Despite these findings the patient obtained a complete morphological and cytogenetic remission of the leukemia following treatment with all-trans-retinoic acid. " 03/01/1995 - "Aucte promyelocytic leukemia (APL) can be treated by all-trans retinoic acid (ATRA) with high complete remission rate. " 11/01/2000 - "Retinoic acid has proved to be an effective treatment for promyelocytic leukemia. " Order ALL the reference details at left...
9.	Vincristine (Oncovin)FDA LinkGeneric 03/01/2006 - "Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study." 10/01/1996 - "In this study, in vitro and in vivo reversion of MDR was attempted in a human leukemia cell line resistant to vincristine (HL-60/Vinc) using an 18-mer mdr1 antisense phosphorothioate oligodeoxynucleotide ([S]ODN) in combination with vincristine. " 01/01/1985 - "A phase II trial of prolonged IV infusions of vincristine was conducted in 21 patients with refractory acute leukemia. " 01/01/1985 - "Phase II trial of vincristine infusion in acute leukemia." 06/01/1970 - "[Studies on the neurotixicity of vincristine in the course of infantile leukemia]" Order ALL the reference details at left...
10.	Doxorubicin (Adriamycin)FDA LinkGeneric 11/01/1996 - "In an actual application, these two kinds of modifications in the previous SRB assay procedure were also proved to be effective in the determination of cytotoxicities of doxorubicin by using human leukemias." 01/01/1997 - "CPA and doxorubicin improved survival in the HL60 leukemia model (P = 0.0018). " 12/01/2008 - "This study was aimed to investigate the effects of low frequency and power ultrasound combined with adriamycin on apoptosis of drug-resistant leukemia cell line K562/A02 in vitro, to find out the parameters of optimal exposure, and to explore the possible mechanism reversing drug-resistance of K562/A02 cells. " 11/01/2008 - "This study was to investigate the antitumor effect of low-frequency ultrasound combined with adriamycin on human leukemia multidrug resistance (MDR) cell line K562/A02. " 04/01/2006 - "In the present study, we demonstrate that PBK is down regulated during doxorubicin induced growth arrest of HL60 promyelocytic leukemia cells at least partly due to cell cycle-specific transcriptional regulation. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 02/01/2002 - "Complete remission was achieved by induction chemotherapy, but as myeloid/NK cell precursor acute leukemia is reported to have an extremely poor prognosis due to frequent relapse, the patient underwent allo PBSCT from her HLA-identical father, together with a myeloablative conditioning regimen. " 05/01/2001 - "BACKGROUND: Leukemia is rare in pregnancy and treatment with intensive, multiagent chemotherapy produces complete remission in most adults, but might have deleterious effects on fetuses. " 01/01/2000 - "However, AML-M3 has a lower first remission rate and a higher morbidity and mortality rate than most of the other acute leukemias when treated with conventional chemotherapy. " 01/01/2000 - "Modern chemotherapy can place most patients with acute leukemia into remission. " 09/01/1995 - "Our results suggest that this conditioning regimen is associated with high but manageable acute toxicity and may be highly effective in controlling leukemia resistant to conventional chemotherapy." Order ALL the reference details at left...
2.	Transplants (Transplant) 10/01/2002 - "It is concluded that the models established in this study are stable and direct with an excellent reproducibility and an accuracy, which can be used to evaluate purging efficacy of leukemia cells in model graft using immunomagnetic selection and the experimental studies on tumorcidal effect in vitro." 09/01/2009 - "We have observed a low relapse rate following CBT among patients with acute leukemias in morphologic complete remission (CR) at the time of myeloablative (MA) transplant. " 05/01/2008 - "Significant associations were found between the risk of relapse or the risk of death during complete remission and the leukemia genotype of mutant NPM1 without FLT3-ITD (hazard ratio, 0.44; 95% confidence interval [CI], 0.32 to 0.61), the mutant CEBPA genotype (hazard ratio, 0.48; 95% CI, 0.30 to 0.75), and the MLL-PTD genotype (hazard ratio, 1.56; 95% CI, 1.00 to 2.43), as well as receipt of a transplant from an HLA-matched related donor (hazard ratio, 0.60; 95% CI, 0.44 to 0.82). " 01/01/2008 - "After achieving complete remission of his leukemia, the patient received an allogeneic hematopoietic stem cell transplant. " 06/01/2007 - "This did not prevent graft-versus-leukemia (GvL) effect of the TK-DLI, since 5 of 7 immunized patients maintained the complete remission achieved prior to immunization. " Order ALL the reference details at left...
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 03/01/1997 - "Allogenic bone marrow transplantation is the treatment of choice in chronic granulocyte leukemia patients, while the best results are achieved when it is performed in the chronic phase of the illness. " 04/01/1994 - "Although allogeneic bone marrow transplantation has been shown to be a highly effective treatment for acute and chronic leukemia, leukemic relapse remains a significant problem. " 04/01/1993 - "The role of total body irradiation (TBI) for allogeneic bone marrow transplantation (BMT) for acute leukemia in first complete remission was reevaluated in this study. " 11/01/2009 - "Acute leukemia therapy regimens may lead to sustained clinical remission of BPDCN, with bone marrow transplantation in first complete remission potentially curative in adult patients." 12/01/2007 - "[Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation]" Order ALL the reference details at left...
4.	Transplantation (Transplant Recipients) 01/01/2008 - "While among all leukemias this transplantation regimen had the best outcome in CML, trials with reduced intensity conditioning regimens (RIC) were rather humbling and recurrence of the neoplastic clone occurred frequently. " 01/01/2001 - "CONCLUSION: GATA-2 transcripts was highly expressed in leukemia patients and had no change in remission but significantly decreased in post-transplantation patients. " 11/01/1997 - "Allogenic transplantation of hematopoietic stem cells from bone marrow or peripheral blood have given the best results in the treatment of acute and chronic leukemia. " 01/01/1993 - "After injection of WEHI-3 leukemia cells, syngeneic BMT cured most of the recipients (62%) and transplantation of (C57xBalb)F1 marrow provided no additional benefit. " 10/01/2009 - "The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. " Order ALL the reference details at left...
5.	Immunotherapy 09/01/1990 - "This system provides an excellent model for examining the efficacy of immunotherapy of leukemias with various mediators and effector mechanisms." 02/01/2007 - "Application of specific immunotherapy is effective in eradication of MRD and one of the immunotherapeutic strategies is induction and re-transfusion of leukemia-specific cytotoxic T lymphocytes (CTLs). " 03/01/1997 - "Our analysis indicates that BMT2 as treatment for leukemia relapse is effective in selected cases, and exploration of pre-BMT treatment and post-BMT immunotherapy is warranted." 09/01/1981 - "The phenotype of T cells therapeutically effective in immunotherapy of advanced Friend virus-induced (FBL) leukemia in vivo and cytotoxic to FBL in vitro was determined. " 09/01/1976 - "The data reviewed in this paper indicate that immunotherapy is effective in prolonging remission and survival in acute and chronic leukemia. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Leukemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1827 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>